Biogen Shares Outstanding 2010-2022 | BIIB

Biogen shares outstanding history from 2010 to 2022. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
  • Biogen shares outstanding for the quarter ending March 31, 2022 were 0.148B, a 3.09% decline year-over-year.
  • Biogen 2021 shares outstanding were 0.15B, a 7.25% decline from 2020.
  • Biogen 2020 shares outstanding were 0.161B, a 13.93% decline from 2019.
  • Biogen 2019 shares outstanding were 0.187B, a 8.72% decline from 2018.
Biogen Annual Shares Outstanding
(Millions of Shares)
2021 150
2020 161
2019 187
2018 205
2017 213
2016 219
2015 231
2014 237
2013 238
2012 240
2011 245
2010 255
2009 289
Biogen Quarterly Shares Outstanding
(Millions of Shares)
2022-03-31 148
2021-12-31 150
2021-09-30 149
2021-06-30 150
2021-03-31 152
2020-12-31 161
2020-09-30 157
2020-06-30 161
2020-03-31 173
2019-12-31 187
2019-09-30 184
2019-06-30 190
2019-03-31 197
2018-12-31 205
2018-09-30 202
2018-06-30 207
2018-03-31 212
2017-12-31 213
2017-09-30 212
2017-06-30 212
2017-03-31 216
2016-12-31 219
2016-09-30 219
2016-06-30 219
2016-03-31 219
2015-12-31 231
2015-09-30 233
2015-06-30 236
2015-03-31 236
2014-12-31 237
2014-09-30 237
2014-06-30 237
2014-03-31 238
2013-12-31 238
2013-09-30 238
2013-06-30 239
2013-03-31 238
2012-12-31 240
2012-09-30 238
2012-06-30 241
2012-03-31 242
2011-12-31 245
2011-09-30 245
2011-06-30 245
2011-03-31 245
2010-12-31 255
2010-09-30 242
2010-06-30 262
2010-03-31 273
2009-12-31 289
2009-09-30 291
2009-06-30 290
2009-03-31 290
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $29.239B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.213B 9.87
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.280B 16.23
Biohaven Pharmaceutical Holding (BHVN) United States $10.017B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.593B 0.00
Emergent Biosolutions (EBS) United States $1.775B 7.60
Arcus Biosciences (RCUS) United States $1.357B 34.40
Myovant Sciences (MYOV) United Kingdom $1.000B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.486B 0.00
Gelesis Holdings (GLS) United States $0.360B 0.00
Zymeworks (ZYME) Canada $0.346B 0.00
Ambrx Biopharma (AMAM) United States $0.149B 0.00
Enzo Biochem (ENZ) United States $0.116B 23.80
SQZ Biotechnologies (SQZ) United States $0.099B 0.00